Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Chemo-surveillance: a novel concept of the natural defence mechanism against cancer.

Liau MC, Szopa M, Burzynski B, Burzynski SR.

Drugs Exp Clin Res. 1987;13 Suppl 1:71-6.

PMID:
3569019
[PubMed - indexed for MEDLINE]
2.

Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy.

Liau MC, Szopa M, Burzynski B, Burzynski SR.

Drugs Exp Clin Res. 1987;13 Suppl 1:61-70.

PMID:
3569018
[PubMed - indexed for MEDLINE]
3.

Theoretical investigations on the structure and potential binding sites of antineoplaston A10 and experimental findings.

Michalska D.

Drugs Exp Clin Res. 1990;16(7):343-9.

PMID:
2092960
[PubMed - indexed for MEDLINE]
4.

Potential utility of antineoplaston A-10 levels in breast cancer.

Badria F, Mabed M, Khafagy W, Abou-Zeid L.

Cancer Lett. 2000 Jul 3;155(1):67-70.

PMID:
10814881
[PubMed - indexed for MEDLINE]
5.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

PMID:
8755117
[PubMed - indexed for MEDLINE]
Free Article
6.

Novel piperidinedione analogs as inhibitors of breast cancer cell growth.

Abou-Zeid LA, el-Mowafy AM, el-Ashmawy MB, Hendry LB, Abdelal AM, Badria FA.

Arch Pharm (Weinheim). 2000 Dec;333(12):431-4.

PMID:
11199474
[PubMed - indexed for MEDLINE]
7.

Antineoplastons: history of the research (I).

Burzynski SR.

Drugs Exp Clin Res. 1986;12 Suppl 1:1-9. Review.

PMID:
3527634
[PubMed - indexed for MEDLINE]
8.

Immune modulatory potentials of antineoplaston A-10 in breast cancer patients.

Badria F, Mabed M, El-Awadi M, Abou-Zeid L, Al-Nashar E, Hawas S.

Cancer Lett. 2000 Aug 31;157(1):57-63.

PMID:
10893443
[PubMed - indexed for MEDLINE]
9.

Stereochemical modelling studies of the interaction of antineoplaston A10 with DNA.

Hendry LB, Muldoon TG, Burzynski SR, Copland JA, Lehner AF.

Drugs Exp Clin Res. 1987;13 Suppl 1:77-81.

PMID:
3569020
[PubMed - indexed for MEDLINE]
10.

Inhibition of spontaneous mouse mammary tumour development by antineoplaston A10.

Muldoon TG, Copland JA, Lehner AF, Hendry LB.

Drugs Exp Clin Res. 1987;13 Suppl 1:83-8.

PMID:
3569021
[PubMed - indexed for MEDLINE]
11.

Antineoplaston treatment for advanced hepatocellular carcinoma.

Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O, Hara H.

Oncol Rep. 1998 Nov-Dec;5(6):1363-7.

PMID:
9769368
[PubMed - indexed for MEDLINE]
12.

A novel strategy for remission induction and maintenance in cancer therapy.

Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H, Nakashima Y.

Oncol Rep. 2002 Jan-Feb;9(1):65-8.

PMID:
11748457
[PubMed - indexed for MEDLINE]
13.

Chemoprevention by antineoplaston A10 of benzo(a)pyrene-induced pulmonary neoplasia.

Kampalath BN, Liau MC, Burzynski B, Burzynski SR.

Drugs Exp Clin Res. 1987;13 Suppl 1:51-5.

PMID:
3569016
[PubMed - indexed for MEDLINE]
14.

Actions of an endogenous antitumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA.

Hendry LB, Muldoon TG.

J Steroid Biochem. 1988;30(1-6):325-8.

PMID:
3133525
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats.

Ashraf AQ, Liau MC, Kampalath BN, Burzynski SR.

Drugs Exp Clin Res. 1987;13 Suppl 1:45-50.

PMID:
3569015
[PubMed - indexed for MEDLINE]
16.

Studies of the release rate and bioavailability of antineoplaston A10 capsule.

Wang H, Xu W, Yuan Y.

Drugs Exp Clin Res. 1990;16(7):357-9.

PMID:
2092962
[PubMed - indexed for MEDLINE]
17.

Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10.

Qu XJ, Cui SX, Tian Z, Li X, Chen MH, Xu WF, Inagaki Y, Deng YB, Makuuchi M, Nakata M, Tang W.

Anticancer Res. 2007 Jul-Aug;27(4B):2427-31.

PMID:
17695534
[PubMed - indexed for MEDLINE]
Free Article
18.

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.

Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD.

Mayo Clin Proc. 1999 Feb;74(2):137-45.

PMID:
10069350
[PubMed - indexed for MEDLINE]
19.

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.

Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y.

Kurume Med J. 1995;42(4):241-9.

PMID:
8667595
[PubMed - indexed for MEDLINE]
Free Article
20.

The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice.

Hashimoto K, Koga T, Shintomi Y, Tanaka M, Kakegawa T, Tsuda H, Hara H.

Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):1-5.

PMID:
2157780
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk